• Threshold Pharmaceuticals Inc., of South San Francisco, reported Phase I results showing that TH-302 demonstrated activity in multiple subjects with relapsed/refractory acute myelogenous leukemia and acute lymphoblastic leukemia, and the maximum tolerated dose was established at 460 mg/m2.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter